These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Carpentier-Edwards porcine bioprostheses: assessment of clinical performance.
    Author: Jamieson WR, Allen P, Ling H, Miyagishima RT, Burr LH, Janusz MT, Gerein AN.
    Journal: Can J Cardiol; 1988 Sep; 4(6):314-21. PubMed ID: 3179794.
    Abstract:
    Carpentier-Edwards porcine bioprostheses have been implanted since 1975, commencing with the previous generation standard prosthesis in that year and the new generation supra-annular prosthesis in 1981. The first 700 operations with each prosthesis were evaluated: Carpentier-Edwards standard porcine bioprosthesis (CE-S), 692 patients (772 valves) and Carpentier-Edwards supra-annular porcine bioprosthesis (CE-SA), 698 patients (756 valves). The incidence of thromboembolism was CE-S 1.4% per patient-year and CE-SA 2.1% per patient-year (hazard interval rates not considered). The rate of structural valve deterioration was CE-S 1.8% per patient-year (79 prostheses) and CE-SA 0.2% (four prostheses). The reoperation rate was 2.5% per patient-year (110 prostheses) for CE-S and for CE-SA it was 0.9% (six prostheses). The late mortality rate was 3.7% per patient-year and 4.2%, respectively. The 10-year freedom rates for CE-S were thromboembolism, 82.7 +/- 2.8%; prosthetic valve endocarditis, 93.5 +/- 1.6%; structural valve deterioration, 77.1 +/- 2.9%; reoperation, 69.9 +/- 3.1%; valve related mortality, 85.9 +/- 2.4%; valve failure, 62.8 +/- 3.2%; treatment failure, 82.0 +/- 2.7%; mortality, reoperation and residual morbidity, 59.5 +/- 3.2%; and all complications, 53.4 +/- 3.1%. The four-year freedom rates for CE-SA were thromboembolism, 93.0 +/- 1.3%; prosthetic valve endocarditis, 98.7 +/- 0.5%; structural valve deterioration, 98.3 +/- 1.0%; reoperation, 95.6 +/- 1.3%; mortality, 97.9 +/- 0.6%; valve failure, 93.6 +/- 1.4%; treatment failure, 94.6 +/- 1.1%; mortality, reoperation and residual morbidity, 90.9 +/- 1.6%; and all complications, 85.6 +/- 1.9%.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]